Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

Bullboard (GREY:IPHAF)

View:
Post by go4futureon Jan 23, 2010 10:26pm

Next Gen Voclosporin...

knowledge is spreading across the globe. India in this case, appears it could be a potentially large Uveitis target market for Lux. According to this 2010 published article, India has more than 3.5 ...more  
Post by hopskipjumpon Jan 22, 2010 3:28pm

still following the money

https://www.crainsnewyork.com/article/20100122/SMALLBIZ/100129952#good tradin'-ot
Post by ISAloser247on Jan 22, 2010 3:17pm

Impertinent view

      Back in the "70's" as was the custom, I indulged in  wheat-based beverages and chemical stimulants.Usually ended up in a state , much like the good ...more  
Comment by WASKERWISKon Jan 21, 2010 4:53pm

RE: Lux Royalty Estimates

Regarding the percentage royalties, ISA (and BioMS) was getting double that in previous deal and the Lux deal was made in the rosy times.  I am betting closer to 20%.Regarding multiples ...more  
Comment by go4futureon Jan 21, 2010 4:37pm

RE: Pertinent news for Voclosporine Lux-ISA

Restasis is also a big factor associated with partnership of Inspire and Allergan. Arcticle is a year old but provides some revenue figures associated with Restasis for both Inspire and Allergan ...more  
Post by professional11on Jan 21, 2010 3:49pm

Lux Royalty Estimates

Royalty Estimates: Medius in 2001 determined that average royalties for pharmaceuticals in the pre-clinical stage ranged from 0-5%, while royalties in Phase I were 5-10% and royalties for launched ...more  
Post by professional11on Jan 21, 2010 3:39pm

Pertinent news for Voclosporine Lux-ISA

Inspire's Prolacria Fails in Phase III Dry Eye StudyShares of Inspire Pharmaceuticals Inc. were down 12 % at noon trading on news that its Phase III study of Prolacria in dry eye disease missed ...more  
Comment by throughmudon Jan 21, 2010 3:27pm

RE: RE: Something's Brewing

This would be a great time for a good news release from, say, Lux that directly impacts ISA. It will take some deal of good news to move ISA's SP out of its state of ennui.mud
Comment by biodelatechon Jan 21, 2010 1:27pm

RE: Re: Kool-Aid Brewing

I would deignore you, if  I had been ignoring you.
Post by ISAloser247on Jan 21, 2010 1:23pm

Re: phoenix rising

          TEEVEE should be re-appearing soon!
Comment by rickkuleszaon Jan 21, 2010 1:17pm

RE: Re: Kool-Aid Brewing

hey, thans for ]relieving me at 20 centsther's more at .195 - go get em !!!
Post by ISAloser247on Jan 21, 2010 12:48pm

Re: Kool-Aid Brewing

    "  Everything is possible in love and dreams",   maybe Novartis, who bought Alcon, who was to buy Lux, is involved?        ...more  
Comment by throughmudon Jan 21, 2010 12:24pm

RE: Something's Brewing

Maybe it's something to do with the late-stage failure of Inspire Pharmaceuticals' Prolacria. Prolacria was inPhase III for treatment of dry eye disease. mud
Comment by labumbaon Jan 21, 2010 12:02pm

RE: RE: RE: Something's Brewing

should be  " hotstocked.com "
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities